Next Post

How small biotech companies can make the most out of today’s deal-making landscape

Deal-generating in oncology stays a warm place, mostly pushed by the immuno-oncology space. The 12 months 2020 was a landmark yr for investment in biotech and pharma, with oncology building a massive part of the offer-earning ($133 billion). In 2021, oncology-targeted offers accounted for a massive proportion of world biopharma […]